Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.630
-0.050 (-1.07%)
At close: Mar 17, 2026, 4:00 PM EDT
4.680
+0.050 (1.08%)
After-hours: Mar 17, 2026, 7:55 PM EDT
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
4.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.11M | -9.18M | -74.67% |
| Dec 31, 2021 | 12.29M | 7.98M | 185.26% |
| Dec 31, 2020 | 4.31M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 23.07M | 8.41M | 57.37% |
| Dec 31, 2017 | 14.66M | 4.67M | 46.80% |
| Dec 31, 2016 | 9.99M | -23.62M | -70.28% |
| Dec 31, 2015 | 33.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPVO News
- 7 days ago - Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Accesswire
- 6 weeks ago - Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - Accesswire
- 2 months ago - Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality - Accesswire
- 2 months ago - Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - Accesswire
- 3 months ago - Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - Accesswire
- 4 months ago - Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Accesswire
- 4 months ago - Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update - Accesswire
- 5 months ago - Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Accesswire